TECX — Tectonic Therapeutic Share Price
0.000.00%
Last trade - 00:00- $406.01m
- $265.64m
- 34
- 23
- 37
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.88 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.06% | ||
| Return on Equity | -84.79% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Directors
- Bruce Booth NEC (46)
- Geoff Mackay PRE (54)
- Erik Ostrowski CFO (48)
- Christopher Mason CSO (63)
- Sean O'Bryan OTH
- Deanna Petersen OTH (59)
- Essra Ridha OTH
- Steven Avruch SEC (60)
- Ian Clark IND (60)
- Phillip Donenberg IND (60)
- Gail Farfel IND (57)
- Annalisa Jenkins IND (55)
- Christopher Paige IND (68)
- Philip Vickers IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 17th, 2015
- Public Since
- June 21st, 2018
- No. of Shareholders
- 37
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 18,671,229
- Address
- 490 Arsenal Way, Suite 210, WATERTOWN, 02472
- Web
- https://tectonictx.com/
- Phone
- +1 3396663320
- Contact
- Daniel Ferry
- Auditors
- Deloitte & Touche LLP
Upcoming Events for TECX
Tectonic Therapeutic Inc Annual Shareholders Meeting
Q2 2025 Tectonic Therapeutic Inc Earnings Release
Q2 2025 Tectonic Therapeutic Inc Earnings Release
Similar to TECX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Tectonic Therapeutic share price?
As of Today at 23:37 UTC, shares in Tectonic Therapeutic are trading at $21.75. This share price information is delayed by 15 minutes.
How has the Tectonic Therapeutic share price performed this year?
Shares in Tectonic Therapeutic last closed at $21.75 and the price had moved by +47.32% over the past 365 days. In terms of relative price strength the Tectonic Therapeutic share price has outperformed the S&P500 Index by +32.85% over the past year.
What are the analyst and broker recommendations for Tectonic Therapeutic?
The overall consensus recommendation for Tectonic Therapeutic is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tectonic Therapeutic dividend yield?
Tectonic Therapeutic does not currently pay a dividend.
Does Tectonic Therapeutic pay a dividend?
Tectonic Therapeutic does not currently pay a dividend.
When does Tectonic Therapeutic next pay dividends?
Tectonic Therapeutic does not currently pay a dividend.
How do I buy Tectonic Therapeutic shares?
To buy shares in Tectonic Therapeutic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tectonic Therapeutic?
As of the previous close price of $21.75, shares in Tectonic Therapeutic had a market capitalisation of $406.01m.
Where are Tectonic Therapeutic shares listed?
Here are the trading details for Tectonic Therapeutic:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TECX
What kind of share is Tectonic Therapeutic?
Based on an overall assessment of its quality, value and momentum Tectonic Therapeutic is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tectonic Therapeutic share price forecast for 2025?
The analyst consensus target price for shares in Tectonic Therapeutic is $74.25. That is 241.46% above the last closing price of $21.75.
Analysts covering Tectonic Therapeutic currently have a consensus Earnings Per Share (EPS) forecast of -$4.47 for the next financial year.
Find out moreWhat is the trend in the Tectonic Therapeutic share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tectonic Therapeutic. Over the past six months, its share price has underperformed the S&P500 Index by -46.56%.
As of the last closing price of $21.75, shares in Tectonic Therapeutic were trading -28.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tectonic Therapeutic PE Ratio?
The Tectonic Therapeutic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tectonic Therapeutic?
Tectonic Therapeutic's management team is headed by:
- Bruce Booth - NEC
- Geoff Mackay - PRE
- Erik Ostrowski - CFO
- Christopher Mason - CSO
- Sean O'Bryan - OTH
- Deanna Petersen - OTH
- Essra Ridha - OTH
- Steven Avruch - SEC
- Ian Clark - IND
- Phillip Donenberg - IND
- Gail Farfel - IND
- Annalisa Jenkins - IND
- Christopher Paige - IND
- Philip Vickers - IND